Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

"A.J.P. is funded by the Wellcome Trust (WT 093768/z/10/z). No competing interests exist for the other authors."

"ARROW was funded by the UK Medical Research Council and the UK Department for International Development (DFID). ViiV Healthcare/GlaxoSmithKline donated first-line drugs for ARROW. ARROW was funded by the UK Medical Research Council and the UK Department for International Development (DFID). ViiV Healthcare/GlaxoSmithKline donated first-line drugs for ARROW. A.J.P. is funded by the Wellcome Trust (WT 093768/z/10/z). No competing interests exist for the other authors. The main ARROW trial was funded by the UK Medical Research Council and the UK Department for International Development (DFID). ViiV Healthcare/GlaxoSmithKline donated first-line drugs for ARROW and provided funding for VL assays. Additional funding for the metabolic sub-study was obtained from Wellcome Trust, UK through Southern Africa Centre for Research Excellence (SACORE) at the UZCHS."